サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1588367

毒性試験アウトソーシング市場規模、シェア、動向分析レポート：方法別、GLP別、最終用途別、地域別、およびセグメント予測、2025年～2030年

Toxicity Testing Outsourcing Market Size, Share & Trends Analysis Report By Method (In Vitro, In Vivo), By GLP (GLP, Non GLP), By End-use, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.03円
毒性試験アウトソーシング市場規模、シェア、動向分析レポート：方法別、GLP別、最終用途別、地域別、およびセグメント予測、2025年～2030年
出版日: 2024年10月29日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

毒性試験アウトソーシング市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の毒性試験アウトソーシング市場規模は、2025年から2030年にかけてCAGR 9.52％を記録し、2030年までに63億6,000万米ドルに達すると予測されています。

前臨床試験の減少率の増加は、毒性試験サービスを含むエンドツーエンドのサービスを提供するCROへの前臨床試験のアウトソーシング需要を刺激しています。また、製薬・バイオ医薬品企業の成長と技術革新の高まり、研究開発の増強、動物使用に関する倫理的懸念の高まりが、市場拡大の原動力となっています。

COVID-19は毒性試験アウトソーシング市場に大きな影響を与えています。この危機の間、ワクチン、医療機器、生物学的製剤の受託研究・製造サービスプロバイダーは、製薬会社、バイオテクノロジー企業、その他のエンドユーザーのニーズを満たす上で主要な役割を果たしました。これらの組織は2019年末から、症状が軽いCOVID-19に苦しむ患者の治療薬として使用できるヘルスケア製品の開発に向けて積極的に取り組んでいます。そして、これらの製品は安全性と有効性を評価するために各段階で毒性試験を必要とするため、市場の成長に寄与しています。

製薬・バイオ医薬品業界の企業は、理解が複雑化する環境の中で事業を展開しています。多くの治療領域における治療法の改善や、遺伝子標的治療薬、生物学的製剤、幹細胞治療薬、その他の治療法などの新しいタイプの治療法の出現により、開発や規制の経路がより複雑になっています。安全で効率的な治療を開発するためには、各段階で毒性試験を実施する必要があり、これが市場の成長を後押ししています。

毒性試験アウトソーシング市場のレポートハイライト

  • 2024年には、in vitroセグメントが市場を独占し、57.97%の収益シェアを占めました。この成長は、製品開発活動の増加、研究開発費の増加、毒性学的意識の高まり、前臨床パイプラインの増加など、いくつかの要因によって促進されると予測されます。
  • 2024年の市場シェアはGLPセグメントが最も大きいです。安全性薬理学、遺伝毒性、反復毒性を含む臨床試験は、ヒトへの安全な曝露のために必須であり、GLPの基準に従って実施されなければならないです。
  • 2024年には、製薬・バイオ医薬品企業が61.41%の収益シェアを占め、市場を独占しました。
  • 2024年の毒性試験アウトソーシング市場は、北米が43.13%の最大シェアで世界市場を独占しました。これは米国とカナダの製薬業界の成長に起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 毒性試験アウトソーシング市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場見通し
  • 市場力学
    • 市場牽引要因分析
    • 市場抑制要因分析
  • 市場分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 毒性試験アウトソーシング市場：方法の推定・動向分析

  • セグメントダッシュボード
  • 世界の毒性試験アウトソーシング市場：方法の変動分析
  • 2018年から2030年までの毒性試験アウトソーシングの規模と動向分析、方法別
  • In vitro
  • In vivo

第5章 毒性試験アウトソーシング市場：GLPの推定・動向分析

  • セグメントダッシュボード
  • 世界の毒性試験アウトソーシング市場：GLP変動分析
  • 世界の毒性試験アウトソーシングの規模と動向分析、GLP別、2018年から2030年
  • GLP
  • 非GLP

第6章 毒性試験アウトソーシング市場：最終用途の推定・動向分析

  • セグメントダッシュボード
  • 世界の毒性試験アウトソーシング市場：最終用途変動分析
  • 世界の毒性試験アウトソーシングの規模と動向分析、最終用途別、2018～2030年
  • 製薬・バイオ医薬品企業
  • 学術研究機関
  • その他

第7章 毒性試験アウトソーシング市場：地域の推定・動向分析

  • 地域別市場シェア分析、2023年および2030年
  • 地域市場ダッシュボード
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 企業分類
  • 企業市況分析、2023年
  • 企業プロファイル
    • Eurofins Scientific
    • SGS SA
    • Charles River Laboratories
    • Thermo Fisher Scientific, Inc
    • Intertek Group plc
    • Catalent, Inc
    • ICON plc
    • Med pace
    • Wuxi AppTec
    • Labcorp Drug Development
図表

List of Tables

  • Table 1. List of Tables
  • Table 2. List of Secondary Sources
  • Table 3. List of Abbreviations
  • Table 4. Global Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 5. Global Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 6. Global Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 7. Global Toxicity Testing Outsourcing, by Region, 2018 - 2030 (USD Million)
  • Table 8. North America Toxicity Testing Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table 9. North America Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 10. North America Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 11. North America Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 12. U.S. Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 13. U.S. Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 14. U.S. Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 15. Canada Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 16. Canada Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 17. Canada Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 18. Mexico Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 19. Mexico Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 20. Mexico Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 21. Europe Toxicity Testing Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table 22. Europe Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 23. Europe Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 24. Europe Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 25. UK Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 26. UK Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 27. UK Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 28. Germany Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 29. Germany Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 30. Germany Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 31. France Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 32. France Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 33. France Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 34. Italy Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 35. Italy Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 36. Italy Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 37. Spain Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 38. Spain Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 39. Spain Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 40. Denmark Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 41. Denmark Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 42. Denmark Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 43. Sweden Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 44. Sweden Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 45. Sweden Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 46. Norway Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 47. Norway Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 48. Norway Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 49. Asia Pacific Toxicity Testing Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table 50. Asia Pacific Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 52. Asia Pacific Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 53. Japan Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 54. Japan Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 55. Japan Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 56. China Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 57. China Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 58. China Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 59. India Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 60. India Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 61. India Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 62. Thailand Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 63. Thailand Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 64. Thailand Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 65. South Korea Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 66. South Korea Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 67. South Korea Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 68. Australia Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 69. Australia Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 70. Australia Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 71. Latin America Toxicity Testing Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table 72. Latin America Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 73. Latin America Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 74. Latin America Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 75. Brazil Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 76. Brazil Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 77. Brazil Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 78. Argentina Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 79. Argentina Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 80. Argentina Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa Toxicity Testing Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 84. Middle East & Africa Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 85. South Africa Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 86. South Africa Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 87. South Africa Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 90. Saudi Arabia Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 91. UAE Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 92. UAE Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 93. UAE Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table 94. Kuwait Toxicity Testing Outsourcing, by Method, 2018 - 2030 (USD Million)
  • Table 95. Kuwait Toxicity Testing Outsourcing, by Glp, 2018 - 2030 (USD Million)
  • Table 96. Kuwait Toxicity Testing Outsourcing, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Toxicity Testing Outsourcing Market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 Toxicity Testing Outsourcing Market snapshot
  • Fig. 11 Toxicity Testing Outsourcing Market driver impact
  • Fig. 12 Toxicity Testing Outsourcing Market restraint impact
  • Fig. 13 Toxicity Testing Outsourcing Market: Method takeaways (USD Million)
  • Fig. 14 Toxicity Testing Outsourcing Market: Method movement analysis
  • Fig. 15 In vitro market, 2018 - 2030 (USD Million)
  • Fig. 16 In vivo market, 2018 - 2030 (USD Million)
  • Fig. 17 Toxicity Testing Outsourcing Market: Glp takeaways (USD Million)
  • Fig. 18 Toxicity Testing Outsourcing Market: Glp movement analysis
  • Fig. 19 GLP market, 2018 - 2030 (USD Million)
  • Fig. 20 Non-GLP market, 2018 - 2030 (USD Million)
  • Fig. 21 Toxicity Testing Outsourcing Market: End use takeaways (USD Million)
  • Fig. 22 Toxicity Testing Outsourcing Market: End use movement analysis
  • Fig. 23 Pharmaceutical and biopharmaceutical companies market, 2018 - 2030 (USD Million)
  • Fig. 24 Academic and research institutes market, 2018 - 2030 (USD Million)
  • Fig. 25 Others market, 2018 - 2030 (USD Million)
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 Regional outlook, 2024 & 2030
  • Fig. 28 North America Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 31 Mexico Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 32 Europe Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 33 UK Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 35 France Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 36 Italy Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 37 Spain companion animal Health market, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 40 Norway Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 41 Asia Pacific Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 42 Japan Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 43 China Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 44 India Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 47 Australia Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 48 Latin America Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 49 Brazil Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East & Africa Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 52 South Africa Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 53 Saudi Arabia Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 54 UAE Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait Toxicity Testing Outsourcing Market, 2018 - 2030 (USD Million)
  • Fig. 56 Market participant categorization
目次
Product Code: GVR-4-68039-978-8

Toxicity Testing Outsourcing Market Growth & Trends:

The global toxicity testing outsourcing market size is expected to reach USD 6.36 billion by 2030, registering a CAGR of 9.52% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing attrition rate in preclinical studies is stimulating demand for the outsourcing of preclinical studies to the CROs, which offer end-to-end services including toxicology testing services. Also, rising growth and innovation in pharmaceutical and biopharmaceutical companies, augment in R&D, and increasing ethical concerns about animal use are driving the enlargement of the market.

COVID-19 has significantly impacted the market for toxicity testing outsourcing. During the crisis, vaccine, medical device, and biologic contract research and manufacturing service providers played a predominant role in meeting the needs of pharmaceutical companies, biotech companies, and other end users. These organizations have been actively working towards the development of healthcare products that can be used as a treatment for patients, suffering from COVID-19 with mild symptoms, since the end of 2019. And these products require toxicity testing at each stage to assess safety and effectiveness, thus contributing to market growth.

Companies in the pharmaceutical and biopharmaceutical industries operate in an environment that is becoming more complex to understand. Improvements in many therapeutic areas, as well as the emergence of new types of therapies such as genetically targeted therapies, biologics, stem cell therapies, and other treatment modalities, have resulted in more complex development and regulatory pathways. To develop a treatment that is secure and efficient, it is necessary to do toxicity testing at each stage, which is boosting the market's growth.

Toxicity Testing Outsourcing Market Report Highlights:

  • In 2024, the in vitro segment dominated the market, accounting for a revenue share of 57.97%. This growth is anticipated to be fueled by several factors, including increased product development activities, rising R&D spending, growing toxicological awareness, and an increasing preclinical pipeline.
  • GLP segment accounted for the larger market share in 2024. Clinical studies, including safety pharmacology, genotoxicity, and repeated toxicity, are mandatory for safe exposure to humans and must be performed as per the standards of GLP.
  • In 2024, the pharmaceutical and biopharmaceutical companies segment dominated the market, accounting for a revenue share of 61.41%.
  • North America toxicity testing outsourcing market dominated the global market in 2024 with the largest share of 43.13%. This can be attributed to the growth of the pharmaceutical industries in the U.S. and Canada.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Toxicity Testing Outsourcing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growth and innovation in the life sciences industry
      • 3.2.1.2. Increased investment in research and development
      • 3.2.1.3. Increasing Complexity in Research and Development
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Monitoring issues and lack of standardization
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Toxicity Testing Outsourcing Market: Method Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Toxicity Testing Outsourcing Market; Method Movement Analysis
  • 4.3. Global Toxicity Testing Outsourcing Size & Trend Analysis, by Method, 2018 to 2030 (USD Million)
  • 4.4. In vitro
    • 4.4.1. In vitro market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. In vivo
    • 4.5.1. In vivo market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Toxicity Testing Outsourcing Market: Glp Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Toxicity Testing Outsourcing Market; Glp Movement Analysis
  • 5.3. Global Toxicity Testing Outsourcing Size & Trend Analysis, by Glp, 2018 to 2030 (USD Million)
  • 5.4. GLP
    • 5.4.1. GLP market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Non GLP
    • 5.5.1. Non GLP market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Toxicity Testing Outsourcing Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Toxicity Testing Outsourcing Market; End Use Movement Analysis
  • 6.3. Global Toxicity Testing Outsourcing Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical and Biopharmaceutical Companies
    • 6.4.1. Pharmaceutical and biopharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Academic and Research Institutes
    • 6.5.1. Academic and research institutes market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Toxicity Testing Outsourcing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Company Market Position Analysis, 2023
  • 8.3. Company Profiles
    • 8.3.1. Eurofins Scientific
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. SGS SA
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Charles River Laboratories
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Thermo Fisher Scientific, Inc
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Intertek Group plc
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Catalent, Inc
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. ICON plc
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Med pace
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Wuxi AppTec
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Labcorp Drug Development
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives